Legend Biotech Corp
corporate_fare Company Profile
Legend Biotech Corp (NASDAQ:LEGN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 35 items for LEGN at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Legend Biotech's LB2501 Achieves 100% ORR, 83% CR in Phase 1 Lymphoma Study, Establishing Clinical Proof-of-Concept
- Legend Biotech Reports Exceptional Phase 1 Data for LB2501 In Vivo CAR-T in R/R B-NHL
- Legend Biotech's novel in vivo CAR-T therapy shows 100% response rate in early blood cancer trial
- Legend Biotech Reports Positive Early Data for Solid Tumor CAR-T (LB2102) and Strong CARVYKTI® Updates at ASCO
- Legend Biotech to Present Positive Early Data for Solid Tumor CAR-T (LB2102) and New CARVYKTI® Analyses at ASCO
Financial Snapshot
Insider Transactions
LEGN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.